http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:01:59 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Bausch+%2B+Lomb+launches+EyeGility+preloaded+IOL+system+in+the+U.S./26776505.html <p>Bausch + Lomb Corporation (NYSE: BLCO) has launched the EyeGility Inserter preloaded intraocular lens (IOL) delivery system in the United States, according to a company statement.</p><p>The EyeGility Inserter is designed for use with the enVista family of IOLs. It features one-handed operation, a silicone soft-tipped plunger, and allows injection through a 2.4mm incision. The system also supports up to 20 minutes of standby time between preparation and lens delivery, according to the company.</p><p>The inserter is currently available with enVista Aspire preloaded IOLs. Compatibility with enVista Envy lenses is expected to become available in the coming months.</p><p>"The launch of EyeGility enables http://www.streetinsider.com/Corporate+News/Bausch+%2B+Lomb+launches+EyeGility+preloaded+IOL+system+in+the+U.S./26776505.html Thu, 16 Jul 2026 07:01:59 -0400 BLCO http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html <ul class="bwlistdisc"> <li> <i>EyeGility is designed for the enVista® family of IOLs</i> </li> <li> <i>Offers balanced push force for smooth delivery, convenient one-handed operation</i> </li> <li> <i>Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months</i> </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260716234280/en/" rel="nofollow">https://www.businesswire.com/news/home/20260716234280/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260716234280/en/2852749/4/EyeGility_Inserter_with_Shuttle_beauty_1.jpg" alt="" /></div><p> “The enVista IOL platform http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Launches+EyeGility%E2%84%A2+Inserter+Preloaded+IOL+Delivery+System+in+the+United+States/26776458.html Thu, 16 Jul 2026 07:00:00 -0400 BHC BLCO BLCO O.00673983 O.54556593 http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html <p>Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did not meet its primary endpoint, and the company will discontinue development of the topical treatment for that indication.</p> <p>The randomized, double-masked, three-arm study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The primary endpoint was a change from baseline in visual field mean deviation at Day 28. Key secondary endpoints related to visual function were also not achieved. One secondary endpoint — a reduction in intraocular pressure at Day 28 — was met. No new safety signals were identified.</p> <p>Bausch http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html Thu, 09 Jul 2026 16:30:52 -0400 A.50216947 BHC BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html <p>Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did not meet its primary endpoint, and the company will discontinue development of the topical treatment for that indication.</p> <p>The randomized, double-masked, three-arm study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The primary endpoint was a change from baseline in visual field mean deviation at Day 28. Key secondary endpoints related to visual function were also not achieved. One secondary endpoint — a reduction in intraocular pressure at Day 28 — was met. No new safety signals were identified.</p> <p>Bausch http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html Thu, 09 Jul 2026 16:30:52 -0400 A.50216947 BHC BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html <p>Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did not meet its primary endpoint, and the company will discontinue development of the topical treatment for that indication.</p> <p>The randomized, double-masked, three-arm study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The primary endpoint was a change from baseline in visual field mean deviation at Day 28. Key secondary endpoints related to visual function were also not achieved. One secondary endpoint — a reduction in intraocular pressure at Day 28 — was met. No new safety signals were identified.</p> <p>Bausch http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html Thu, 09 Jul 2026 16:30:52 -0400 A.50216947 BHC BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html <p>Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did not meet its primary endpoint, and the company will discontinue development of the topical treatment for that indication.</p> <p>The randomized, double-masked, three-arm study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The primary endpoint was a change from baseline in visual field mean deviation at Day 28. Key secondary endpoints related to visual function were also not achieved. One secondary endpoint — a reduction in intraocular pressure at Day 28 — was met. No new safety signals were identified.</p> <p>Bausch http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html Thu, 09 Jul 2026 16:30:52 -0400 A.50216947 BHC BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html <p>Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did not meet its primary endpoint, and the company will discontinue development of the topical treatment for that indication.</p> <p>The randomized, double-masked, three-arm study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The primary endpoint was a change from baseline in visual field mean deviation at Day 28. Key secondary endpoints related to visual function were also not achieved. One secondary endpoint — a reduction in intraocular pressure at Day 28 — was met. No new safety signals were identified.</p> <p>Bausch http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html Thu, 09 Jul 2026 16:30:52 -0400 A.50216947 BHC BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html <p>Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did not meet its primary endpoint, and the company will discontinue development of the topical treatment for that indication.</p> <p>The randomized, double-masked, three-arm study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The primary endpoint was a change from baseline in visual field mean deviation at Day 28. Key secondary endpoints related to visual function were also not achieved. One secondary endpoint — a reduction in intraocular pressure at Day 28 — was met. No new safety signals were identified.</p> <p>Bausch http://www.streetinsider.com/FDA/Bausch+%2B+Lomb+glaucoma+eye+drop+fails+Phase+2+trial/26753592.html Thu, 09 Jul 2026 16:30:52 -0400 A.50216947 BHC BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Press+Releases/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593 http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html <ul class="bwlistdisc"> <li> Phase 2 study did not meet its primary endpoint. </li> <li> Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. </li> <li> Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. </li> </ul> <p> VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study http://www.streetinsider.com/Business+Wire/Bausch+%2B+Lomb+Announces+Phase+2+Results+for+Glaucoma+Neuroprotective+Candidate/26753575.html Thu, 09 Jul 2026 16:30:00 -0400 A.50216947 BHC BLCO BLCO O.00673983 O.48249787 O.54556593